Updates are available Correction dated 2025-04-14
Click to view Correction: https://doi.org/10.1186/s12885-025-13994-4
-
Authors
Roux, Alexandra
Hervouet, Lucile
Stefano, Francesca Di
French, David P.
Giordano, Livia
Ritchie, David
Bugat, Marie-Eve Rougé
Keatley, Debbie
Cholerton, Rachel
McWilliams, Lorna
Rossi, Paolo Giorgi
Balleyguier, Corinne
Guindy, Michal
Gilbert, Fiona J.
Burrion, Jean-Benoit
Roman, Marta
Vissac-Sabatier, Cécile
Couch, Daniel
Delaloge, Suzette
Montgolfier, Sandrine de
,
-
Funding
Funding for this research was provided by:
European Union’s Horizon 2020 research and innovation programme (N°755394)
NIHR Biomedical Research Centre in Manchester (IS-BRC-1215-20007)
PHRC-K research-funding programme France (17-154)
NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
Instituto de Salud Carlos III FEDER SPAIN (PI19/00007)
Institut National Du Cancer (INCa/16048)
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 2 March 2025
First Online: 15 March 2025
Change Date: 14 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12885-025-13994-4
Declarations
:
: This study was performed in accordance with relevant guidelines and regulations. This study is a planned sub-study of the MyPeBS trial which has obtained an Ethics Committee approval by a French Ethics Commitee (Comité de protection des personnes Sud Ouest et outre mer IV Limoges CPP18-056a / 2018-A00535-50, August 30th 2018) as well as in each participating country. The French data protection agency (CNIL: Commission nationale de l’informatique et des libertés) granted MyPeBS an authorization for data collection and processing on July 1st, 2019 (Decision DR-2019-168). Every professional received information and consent to participate. This study doesn’t report any use of animal or human data or tissue.
: Not applicable.
: The authors declare no competing interests.
